Selected Sensitive CYP2D6 Substrates/Mirabegron
This information is generalized and not intended as specific medical advice. Consult your healthcare professional before taking or discontinuing any drug or commencing any course of treatment.
Medical warning:
Moderate. These medicines may cause some risk when taken together. Contact your healthcare professional (e.g. doctor or pharmacist) for more information.
How the interaction occurs:
Mirabegron may increase the amount of atomoxetine, clomipramine, duloxetine, imipramine, metoprolol or nortriptyline in your blood by slowing down how quickly your liver processes these medicines.
What might happen:
Your blood levels of atomoxetine, clomipramine, duloxetine, imipramine, metoprolol or nortriptyline may increase and could cause toxic effects.
What you should do about this interaction:
Let your healthcare professionals (e.g. doctor or pharmacist) know that you are taking these medicines together.Your healthcare professionals may already be aware of this interaction and may be monitoring you for it. Keep all of your appointments with the doctor and laboratory. Do not start, stop, or change the dosage of any medicine before checking with them first.
References:
1.Myrbetriq (mirabegron) prescribing information. Astellas Pharma Technologies, Inc. June 2012.
2.US Food and Drug Administration (FDA). Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers. Available at: http://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/D rugInteractionsLabeling/ucm093664.htm. Updated 08/05/2011.
